Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. INMD
INMD logo

INMD Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Inmode Ltd (INMD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
14.400
1 Day change
0.63%
52 Week Range
16.740
Analysis Updated At
2026/05/01
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

INMD is not a strong buy right now for a beginner focused on long-term investing, even with $50,000-$100,000 available. The stock is trading weakly in pre-market at 14.42 and lacks a clear bullish catalyst, while the latest quarter showed revenue growth but much weaker profitability. With no AI Stock Picker or SwingMax signal today, neutral hedge/insider activity, and no recent news-driven upside, the best call is to wait rather than buy aggressively now.

Technical Analysis

Technically, INMD is in a mixed-to-slightly weak setup. The MACD histogram is slightly negative and still below zero, though negatively contracting, which suggests downside momentum is not strong but the trend is not firmly bullish. RSI_6 at 60.78 is neutral to mildly positive, and moving averages are converging, indicating a lack of clear trend direction. Price is near the pivot at 14.382 and below resistance at 14.733, so the stock needs a breakout to confirm strength. Near-term pattern data also points to limited upside, with a projected -5.47% move over the next month.

Options Data

Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

Options sentiment is mixed but leans cautious. The open interest put-call ratio of 0.81 is not heavily bearish, but the option volume put-call ratio of 2.71 shows much heavier put volume than call volume today, which suggests traders are positioning defensively. Implied volatility at 41.75 is elevated versus historical volatility of 23, and today’s options activity is below average in total volume, so there is no strong conviction signal from the options market.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
3
Buy
7

Positive Catalysts

  • ["Revenue grew 6.13% YoY in Q4 2025, showing the business is still expanding top-line.", "Baird raised its price target to $17 from $16 after Q4 results, which is a modest positive adjustment.", "No major negative news in the last week, so there is no fresh event-driven deterioration."]

Neutral/Negative Catalysts

  • ["Net income fell 67.35% YoY and EPS fell 62.83% YoY in the latest quarter, showing major profit pressure.", "Gross margin declined to 78.28%, indicating some margin compression.", "No recent news catalysts, so there is nothing to drive immediate upside.", "Hedge funds and insiders are neutral, with no significant buying trend.", "No recent congress trading data or influential figure transactions were reported.", "Options flow shows notably stronger put volume than call volume."]

Financial Performance

In the latest reported quarter, Q4 2025, InMode posted revenue of $103.854M, up 6.13% YoY, which is positive for growth. However, profitability weakened sharply: net income dropped 67.35% YoY to $27.025M and EPS fell 62.83% YoY to $0.42. Gross margin also slipped to 78.28%, down 1.34% YoY. Overall, the latest quarter shows revenue growth but clear earnings and margin pressure.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent analyst action is mildly positive but still cautious. On 2026-02-11, Baird's Jeff Johnson raised the price target on InMode to $17 from $16 after Q4 results, but kept a Neutral rating. That means Wall Street sees some upside from current levels, but the overall pros view remains balanced rather than bullish: modest target increase, no upgrade, and no strong consensus buy signal.

Wall Street analysts forecast INMD stock price to rise
5 Analyst Rating
Wall Street analysts forecast INMD stock price to rise
1 Buy
4 Hold
0 Sell
Hold
Current: 14.310
sliders
Low
15
Averages
17.33
High
21
Current: 14.310
sliders
Low
15
Averages
17.33
High
21
Baird
Jeff Johnson
Neutral
maintain
$16 -> $17
AI Analysis
2026-02-11
Reason
Baird
Jeff Johnson
Price Target
$16 -> $17
AI Analysis
2026-02-11
maintain
Neutral
Reason
Baird analyst Jeff Johnson raised the firm's price target on InMode to $17 from $16 and keeps a Neutral rating on the shares. The firm updated its model following Q4 results.
Canaccord
Hold
downgrade
$16 -> $15
2025-12-17
Reason
Canaccord
Price Target
$16 -> $15
2025-12-17
downgrade
Hold
Reason
Canaccord lowered the firm's price target on InMode to $15 from $16 and keeps a Hold rating on the shares. The firm said they are bullish on the Med-Tech sector heading into 2026 as they expect investor interest given smid-cap valuations continue to remain depressed, while M&A has picked up and the IPO market has opened in some respects. They also highlight how AI is changing our space, enabling improved patient outcomes, increased procedure volumes, more efficiency at the corporate level, and improved surgical accuracy/reproducibility, which they believe could drive some of the greatest changes in healthcare at a time when the system is capacity constrained and in desperate need of solutions.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for INMD
Unlock Now

People Also Watch